Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC
By
Lorenzo De Sanctis
Riccardo Ray Colciago
Giulia Rossano
Matteo Ferrari
Matteo Mombelli
Ilenia Manno
Federica Ferrario
Sara Saufi
Valeria Faccenda
Denis Panizza
Gaia Passarella
Stefania Canova
Diego Luigi Cortinovis
Stefano Arcangeli
May 25, 2026
Clinical Scorecard: Ablative Radiotherapy Targeted at Progression Enhances Event-Free Survival in Oligoprogressive Non-Small Cell Lung Cancer
At a Glance
Category Detail
Condition Oligoprogressive Non-Small Cell Lung Cancer (NSCLC) Key Mechanisms Progression-directed radiation therapy (PDRT) targeting oligoprogressive lesions to maintain disease control. Target Population Patients with oligoprogressive NSCLC after initial systemic therapy. Care Setting Single-center retrospective analysis.
Key Highlights
Median event-free survival (EFS) of 5 months. One-year actuarial EFS rate of 52.1%. PDRT associated with improved EFS when directed at primary tumor. Complete response prior to oligoprogression linked to better outcomes. Chemotherapy use correlated with worse outcomes. Guideline-Based Recommendations
Diagnosis
Oligoprogression defined as progression involving fewer than five extracranial lesions or total intracranial disease volume of ≤14 cc. Management
PDRT administered after first-line systemic therapy. Monitoring & Follow-up
Regular imaging (CT, PET/CT, MRI) every 3–4 months to assess oligoprogression. Risks
Larger cumulative tumor volume associated with worse outcomes. Patient & Prescribing Data
Eighty-seven patients with oligoprogressive NSCLC.
PDRT may extend median time to next treatment to 8 months.
Clinical Best Practices
Multidisciplinary team discussions to define optimal therapeutic approaches. Related Resources & Content
